Detaram HD, Joachim N, Liew G, et al. - In this investigation, researchers explored the connection between smoking and age of onset of neovascular age-related macular degeneration (nAMD), visual acuity (VA), central macular thickness (CMT) and the presence of fluid in nAMD patients. During 2012–2015, 547 patients with nAMD were selected from a tertiary eye clinic. Of these, 12 months later, 490 patients were followed up. A retinal expert verified the clinical diagnosis of nAMD. Current smokers developed nAMD at an average of 5.5 years younger age than never smokers and 4.4 years younger age than former smokers after multivariable adjustment. At baseline, the adjusted mean CMT in current was significantly higher than in past smokers. Current smoking was linked to a younger age of nAMD onset and key treatment outcomes like higher mean CMT and greater odds of subretinal fluid presence. These results indicate that cessation of smoking may benefit nAMD-treated patients.